Angus Russell
Chairman at REVANCE THERAPEUTICS, INC.
Net worth: 233 777 $ as of 2024-05-30
Profile
Angus C.
Russell is currently the Non-Executive Chairman at Revance Therapeutics, Inc. and an Independent Director at Lineage Cell Therapeutics, Inc. Previously, he served as the Chief Executive Officer & Director at Shire Plc from 2008 to 2013.
He was also the Chairman at Mallinckrodt Plc from 2018 to 2022.
Additionally, he held positions such as Director at Questcor Pharmaceuticals, Inc., Independent Director at InterMune, Inc., Non-Executive Director at The City of London Investment Trust Plc, and Non-Executive Director at Investment Trust Ltd.
He served as the Chief Financial Officer & Director at Shire Acquisition, Inc. and Vice President-Corporate Finance at AstraZeneca PLC.
He was a Principal at Imperial Chemical Industries Ltd.
and Treasurer at Zeneca Garden Care.
Currently, Mr. Russell is also an Independent Director at TherapeuticsMD, Inc.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-04-30 | 51,506 ( 0.05% ) | 146 277 $ | 2024-05-30 | |
2024-04-24 | 87,500 ( 0.05% ) | 87 500 $ | 2024-05-30 |
Angus Russell active positions
Companies | Position | Start |
---|---|---|
REVANCE THERAPEUTICS, INC. | Chairman | 2011-02-28 |
LINEAGE CELL THERAPEUTICS, INC. | Director/Board Member | 2014-12-08 |
Former positions of Angus Russell
Companies | Position | End |
---|---|---|
THERAPEUTICSMD, INC. | Director/Board Member | 2022-12-29 |
MALLINCKRODT PLC | Chairman | 2022-06-15 |
INTERMUNE INC | Director/Board Member | 2014-08-31 |
QUESTCOR PHARMACEUTICALS INC | Director/Board Member | 2014-08-13 |
SHIRE | Chief Executive Officer | 2013-03-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
ASTRAZENECA PLC | Health Technology |
REVANCE THERAPEUTICS, INC. | Health Technology |
MALLINCKRODT PLC | Health Technology |
LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
THERAPEUTICSMD, INC. | Health Technology |
Private companies | 9 |
---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Imperial Chemical Industries Ltd.
Imperial Chemical Industries Ltd. Chemicals: Major DiversifiedProcess Industries Imperial Chemical Industries Ltd. manufactures chemicals and paint products. Its products include coatings, adhesives, starch, and synthetic polymer. The company was founded on December 7, 1926 and is headquartered in Slough, the United Kingdom. | Process Industries |
The City of London Investment Trust Plc
The City of London Investment Trust Plc Financial ConglomeratesFinance The City of London Investment Trust Plc is a closed-end investment trust. It seeks to provide long-term growth in income and capital, principally by investment in the United Kingdom equities, with a bias towards large, multinational companies. The company was founded in 1860 and is headquartered in London, the United Kingdom. | Finance |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | Health Technology |
Investment Trust Ltd. | |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
- Stock Market
- Insiders
- Angus Russell